World Journal of Clinical Oncology - Baishideng Publishing Group

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 16, Issue 11

Peer-Review Report of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

All Articles published online

Item

Count

PDF

HTML

393

Figures (1-2)

Tables (1-3)

Sum=490

Publishing Process of This Article

Item

Count

Browse

105

Download

226

Sum=331

Nov 24, 2025 (publication date) through Apr 25, 2026

Times Cited of This Article

Journal Information of This Article

Publication Name

World Journal of Clinical Oncology

ISSN

2218-4333

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Cited by in CrossRef

For:	Badroon NA, Alsalahi A, Aljaberi MA, Abdul Majid N, Alshawsh MA. Cardamonin as a potential anticancer agent: Preclinical insights and clinical implications. World J Clin Oncol 2025; 16(11): 110911 [PMID: 41355908 DOI: 10.5306/wjco.v16.i11.110911]
URL:	https://www.wjgnet.com/2218-4333/full/v16/i11/110911.htm

Number	Citing Articles
1	Aizhi Zhang, AbdulRahman Muthanna, Yu Zhao Lee, Xuan Xin Yew, Rieyshmondraj Selvanathan, Zuo Shan Reuel Gan, Ji Wei Tan, Yu-Cheng Ho, Ming Tatt Lee, Chau Ling Tham. Pharmacological effects of cardamonin in metabolic diseases: a review on preclinical studies. Inflammopharmacology 2026; 34(4): 2317 doi: 10.1007/s10787-026-02191-9
2	Yezi Xia, Yinwei Zhang, Ying Li, Xiaojing Li, Yaling Wu, Qi Yao. Cardamonin ameliorates neuroinflammation in Parkinson’s disease by regulating NF-κB signaling. Hereditas 2026; 163(1) doi: 10.1186/s41065-026-00660-3